Y-Biologics, Inc. (KOSDAQ:338840)
South Korea · Delayed Price · Currency is KRW 13,850
+970 (7.53%)
At close: Sep 12, 2025
Y-Biologics Cash Flow Statement
Financials in millions KRW. Fiscal year is January - December.
Millions KRW. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2017 - 2020 |
|---|---|---|---|---|---|---|---|
Period Ending | Jun '25 Jun 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2017 - 2020 |
Net Income | -6,192 | -6,442 | -20,871 | -18,804 | -17,071 | -10,029 | Upgrade |
Depreciation & Amortization | 1,949 | 2,038 | 2,354 | 2,962 | 2,316 | 1,469 | Upgrade |
Loss (Gain) From Sale of Assets | 15.62 | 0 | -329.65 | 172.61 | -15.23 | - | Upgrade |
Stock-Based Compensation | 632.84 | 1,189 | 2,097 | 2,607 | 1,570 | 1,169 | Upgrade |
Provision & Write-off of Bad Debts | 142.69 | 300.68 | - | 425.54 | - | - | Upgrade |
Other Operating Activities | 238.66 | -1,486 | 10,736 | 207.98 | -331.6 | 2,144 | Upgrade |
Change in Accounts Receivable | 38.29 | 233.33 | 116.51 | -290.23 | -577.53 | -245.68 | Upgrade |
Change in Accounts Payable | 0.44 | 2.02 | 1.21 | - | - | - | Upgrade |
Change in Unearned Revenue | - | - | - | 41.03 | - | - | Upgrade |
Change in Income Taxes | - | - | -84.38 | 84.38 | - | - | Upgrade |
Change in Other Net Operating Assets | 461.55 | 21.86 | -1,627 | 2,490 | 4,941 | -5,476 | Upgrade |
Operating Cash Flow | -2,713 | -4,143 | -7,607 | -10,105 | -9,168 | -10,968 | Upgrade |
Capital Expenditures | -436.97 | -2,860 | -193.42 | -1,088 | -7,552 | -777.69 | Upgrade |
Sale of Property, Plant & Equipment | 6.68 | - | 963.98 | 237.65 | - | - | Upgrade |
Sale (Purchase) of Intangibles | -200 | - | -2.72 | -9.07 | -18.61 | -165.15 | Upgrade |
Investment in Securities | 8,239 | -2,750 | -250 | - | - | - | Upgrade |
Other Investing Activities | 32.83 | 187.84 | 3,197 | 100.51 | -325.43 | -65.22 | Upgrade |
Investing Cash Flow | 7,642 | -5,422 | 3,715 | -759.15 | -7,896 | -998.06 | Upgrade |
Long-Term Debt Issued | - | - | 500 | - | - | - | Upgrade |
Short-Term Debt Repaid | - | -2,000 | - | - | - | - | Upgrade |
Long-Term Debt Repaid | - | -193.97 | -2,781 | -803.57 | -356.89 | -275.35 | Upgrade |
Total Debt Repaid | -167.01 | -2,194 | -2,781 | -803.57 | -356.89 | -275.35 | Upgrade |
Net Debt Issued (Repaid) | -167.01 | -2,194 | -2,281 | -803.57 | -356.89 | -275.35 | Upgrade |
Issuance of Common Stock | 131.63 | 201.23 | 14,063 | 49.52 | 604.89 | 20,163 | Upgrade |
Other Financing Activities | 36 | 65 | -0 | -0 | -0 | - | Upgrade |
Financing Cash Flow | 0.62 | -1,928 | 11,782 | 6,896 | 247.99 | 19,888 | Upgrade |
Foreign Exchange Rate Adjustments | 5.25 | 40.24 | 32.59 | -290.95 | 300.15 | -49.7 | Upgrade |
Net Cash Flow | 4,934 | -11,452 | 7,922 | -4,259 | -16,516 | 7,872 | Upgrade |
Free Cash Flow | -3,150 | -7,003 | -7,801 | -11,193 | -16,720 | -11,745 | Upgrade |
Free Cash Flow Margin | -52.86% | -121.52% | -224.21% | -269.68% | -344.94% | -174.48% | Upgrade |
Free Cash Flow Per Share | -213.25 | -468.82 | -623.04 | -910.72 | -1374.20 | -1177.03 | Upgrade |
Cash Interest Paid | 47.08 | 51.43 | 142.22 | 95.56 | 88.47 | 128 | Upgrade |
Cash Income Tax Paid | - | 61.62 | 2.89 | -7.34 | 4.1 | -61.45 | Upgrade |
Levered Free Cash Flow | -1,883 | -5,270 | -5,629 | -7,303 | -20,134 | -15,151 | Upgrade |
Unlevered Free Cash Flow | -1,860 | -5,243 | -5,539 | -7,238 | -20,062 | -14,872 | Upgrade |
Change in Working Capital | 500.28 | 257.21 | -1,593 | 2,325 | 4,364 | -5,721 | Upgrade |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.